Empirical Bioscience has been acquired by Fortis Life Sciences
The owner of Empirical Bioscience has sold the company to Fortis Life Sciences.
Empirical Bioscience is a leading developer and manufacturer of enzymes, proteins and reagents for molecular biology and life science applications. Empirical focuses on supplying premium, quality and custom-configured products to the life sciences industry for both research and commercial applications. The company has a comprehensive library of products that can be readily configured to customer specifications and offers technical support to assist with the development and launch of assays and products.
Fortis Life Sciences is a strategic platform providing capital, expertise and operational resources enabling the growth and success of founder-led life science tools companies.
One of Oaklins’ teams in the USA served as the financial advisor to Empirical Bioscience in its sale to Fortis Life Sciences.
Talk to the deal team
Bradford A. Adams
Oaklins TM Capital
Michael S. Goldman
Oaklins TM Capital
Harrison P. Boeschenstein
Oaklins TM Capital
Related deals
White Lab has acquired Testing
White Lab Srl. has acquired Testing Srl.
Learn morePrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Learn moreCara Care has been acquired by Mahana Therapeutics
Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.
Learn more